ScreenerHero

TRLV Trulieve Cannabis Corp.

Partial data
AMEX · US · Healthcare · Drug Manufacturers - Specialty & Generic · trulieve.com
11.07USD-4.98%Mkt Cap: 2.21B $P/E: —

Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through hom…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.69BUSDP/E 25.5
TAK
Takeda Pharmaceutical Company Limited
$57.82BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.64BUSDP/E 65.2
HLN
Haleon plc
$39.01BUSDP/E 18.1
ZTS
Zoetis Inc.
$29.48BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
UTHR
United Therapeutics Corporation
$23.23BUSDP/E 19.4
VTRS
Viatris Inc.
$20.15BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.27BUSDP/E 111.6
NBIX
Neurocrine Biosciences, Inc.
$14.79BUSDP/E 21.3
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.23BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.40BUSDP/E 28.4
KRK
Krka, d. d.
$8.63BUSDP/E 19.3
AMRX
Amneal Pharmaceuticals, Inc.
$7.07BUSDP/E 41.4
ALKS
Alkermes plc
$6.99BUSDP/E 109.6
HIMS
Hims & Hers Health, Inc.
$6.88BUSD
LNTH
Lantheus Holdings, Inc.
$6.53BUSDP/E 24.2
KNSA
Kiniksa Pharmaceuticals International, plc
$5.93BUSDP/E 77.9
APTX
Apotex Health Corp.
$5.27BUSD
HeadlineSourceTime
Older
Trulieve Cannabis Q2 Earnings Call Highlights

Trulieve Cannabis (NYSE:TRLV) reported second-quarter revenue of $271 million, while outlining plans to expand in Georgia and Texas following changes in medical cannabis regulations and the company’s June listing on the New York Stock Exchange. The company said reported second-quarter results inclu

MarketBeat
Trulieve Cannabis (TRLV) Reports Steeper Losses And Lower Sales, Is The Valuation Discount Justified?

Trulieve Cannabis earnings and what changed Trulieve Cannabis (TRLV) reported second quarter 2026 results that drew attention. Sales for the quarter were US$271 million with a net loss of US$406 million, compared with smaller losses and higher sales a year earlier. Over the first half of 2026, sales were US$557.7 million and the company reported a net loss of US$403.6 million. Loss per share from continuing operations increased sharply for both the quarter and six month periods. See our...

Simply Wall St.
Trulieve Shares Advance After Earnings Beat Despite Revenue Miss

Trulieve Cannabis Corp. (NYSE:TRLV) reported stronger-than-expected second-quarter earnings, with investors focusing on improved profitability even though revenue came in slightly below market forecasts.

InvestorsHub
Should You Buy, Hold or Sell GTBIF Stock Post Q2 Earnings Release?

Green Thumb tops Q2 earnings and sales estimates, but can regulatory catalysts, buybacks and expansion plans outweigh pricing pressure and fierce competition?

Zacks
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Trulieve and Green Thumb were Named Among TIME’s America’s Best Companies of 2026 Curaleaf Holdings Options Set to Begin Trading on Montréal Exchange Aurora Cannabis Earned TIME Canada Recognition, As the Company Announced Plans to Strengthen Governance Ahead of Annual Meeting Key Takeaways; Psychedelic Sector Compass Pathways Strengthened Case for FDA […]

Market Exclusive